229 related articles for article (PubMed ID: 33664846)
1. Aldehyde dehydrogenase inhibitors promote DNA damage in ovarian cancer and synergize with ATM/ATR inhibitors.
Grimley E; Cole AJ; Luong TT; McGonigal SC; Sinno S; Yang D; Bernstein KA; Buckanovich RJ
Theranostics; 2021; 11(8):3540-3551. PubMed ID: 33664846
[No Abstract] [Full Text] [Related]
2. The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.
Vendetti FP; Lau A; Schamus S; Conrads TP; O'Connor MJ; Bakkenist CJ
Oncotarget; 2015 Dec; 6(42):44289-305. PubMed ID: 26517239
[TBL] [Abstract][Full Text] [Related]
3. A putative role for ALDH inhibitors and chemoprevention of BRCA-mutation-driven tumors.
McGonigal S; Wu R; Grimley E; Turk EG; Zhai Y; Cho KR; Buckanovich RJ
Gynecol Oncol; 2023 Sep; 176():139-146. PubMed ID: 37535994
[TBL] [Abstract][Full Text] [Related]
4. Ku70/80 modulates ATM and ATR signaling pathways in response to DNA double strand breaks.
Tomimatsu N; Tahimic CG; Otsuki A; Burma S; Fukuhara A; Sato K; Shiota G; Oshimura M; Chen DJ; Kurimasa A
J Biol Chem; 2007 Apr; 282(14):10138-45. PubMed ID: 17272272
[TBL] [Abstract][Full Text] [Related]
5. Investigation of switch from ATM to ATR signaling at the sites of DNA damage induced by low and high LET radiation.
Saha J; Wang M; Cucinotta FA
DNA Repair (Amst); 2013 Dec; 12(12):1143-51. PubMed ID: 24238855
[TBL] [Abstract][Full Text] [Related]
6. A synthetic lethal screen reveals enhanced sensitivity to ATR inhibitor treatment in mantle cell lymphoma with ATM loss-of-function.
Menezes DL; Holt J; Tang Y; Feng J; Barsanti P; Pan Y; Ghoddusi M; Zhang W; Thomas G; Holash J; Lees E; Taricani L
Mol Cancer Res; 2015 Jan; 13(1):120-9. PubMed ID: 25232030
[TBL] [Abstract][Full Text] [Related]
7. Selective Inhibition of ATM-dependent Double-strand Break Repair and Checkpoint Control Synergistically Enhances the Efficacy of ATR Inhibitors.
Turchick A; Zimmermann A; Chiu LY; Dahmen H; Elenbaas B; Zenke FT; Blaukat A; Vassilev LT
Mol Cancer Ther; 2023 Jul; 22(7):859-872. PubMed ID: 37079339
[TBL] [Abstract][Full Text] [Related]
8. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
[TBL] [Abstract][Full Text] [Related]
9. Targeting ATM and ATR for cancer therapeutics: Inhibitors in clinic.
Priya B; Ravi S; Kirubakaran S
Drug Discov Today; 2023 Aug; 28(8):103662. PubMed ID: 37302542
[TBL] [Abstract][Full Text] [Related]
10. Palbociclib enhances radiosensitivity of hepatocellular carcinoma and cholangiocarcinoma via inhibiting ataxia telangiectasia-mutated kinase-mediated DNA damage response.
Huang CY; Hsieh FS; Wang CY; Chen LJ; Chang SS; Tsai MH; Hung MH; Kuo CW; Shih CT; Chao TI; Chen KF
Eur J Cancer; 2018 Oct; 102():10-22. PubMed ID: 30103095
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of ATM Induces Hypersensitivity to Proton Irradiation by Upregulating Toxic End Joining.
Zhou Q; Howard ME; Tu X; Zhu Q; Denbeigh JM; Remmes NB; Herman MG; Beltran CJ; Yuan J; Greipp PT; Boughey JC; Wang L; Johnson N; Goetz MP; Sarkaria JN; Lou Z; Mutter RW
Cancer Res; 2021 Jun; 81(12):3333-3346. PubMed ID: 33597272
[TBL] [Abstract][Full Text] [Related]
12. Single-stranded DNA orchestrates an ATM-to-ATR switch at DNA breaks.
Shiotani B; Zou L
Mol Cell; 2009 Mar; 33(5):547-58. PubMed ID: 19285939
[TBL] [Abstract][Full Text] [Related]
13. Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair.
Lima M; Bouzid H; Soares DG; Selle F; Morel C; Galmarini CM; Henriques JA; Larsen AK; Escargueil AE
Oncotarget; 2016 May; 7(18):25885-901. PubMed ID: 27029031
[TBL] [Abstract][Full Text] [Related]
14. Depletion of ATR selectively sensitizes ATM-deficient human mammary epithelial cells to ionizing radiation and DNA-damaging agents.
Cui Y; Palii SS; Innes CL; Paules RS
Cell Cycle; 2014; 13(22):3541-50. PubMed ID: 25483091
[TBL] [Abstract][Full Text] [Related]
15. A Pan-ALDH1A Inhibitor Induces Necroptosis in Ovarian Cancer Stem-like Cells.
Chefetz I; Grimley E; Yang K; Hong L; Vinogradova EV; Suciu R; Kovalenko I; Karnak D; Morgan CA; Chtcherbinine M; Buchman C; Huddle B; Barraza S; Morgan M; Bernstein KA; Yoon E; Lombard DB; Bild A; Mehta G; Romero I; Chiang CY; Landen C; Cravatt B; Hurley TD; Larsen SD; Buckanovich RJ
Cell Rep; 2019 Mar; 26(11):3061-3075.e6. PubMed ID: 30865894
[TBL] [Abstract][Full Text] [Related]
16. Specific Human ATR and ATM Inhibitors Modulate Single Strand DNA Formation in
da Silva RB; Bertoldo WDR; Naves LL; de Vito FB; Damasceno JD; Tosi LRO; Machado CR; Pedrosa AL
Front Cell Infect Microbiol; 2021; 11():802613. PubMed ID: 35059327
[No Abstract] [Full Text] [Related]
17. A New Class of Selective ATM Inhibitors as Combination Partners of DNA Double-Strand Break Inducing Cancer Therapies.
Zimmermann A; Zenke FT; Chiu LY; Dahmen H; Pehl U; Fuchss T; Grombacher T; Blume B; Vassilev LT; Blaukat A
Mol Cancer Ther; 2022 Jun; 21(6):859-870. PubMed ID: 35405736
[TBL] [Abstract][Full Text] [Related]
18. ATM and ATR as therapeutic targets in cancer.
Weber AM; Ryan AJ
Pharmacol Ther; 2015 May; 149():124-38. PubMed ID: 25512053
[TBL] [Abstract][Full Text] [Related]
19. DNA Double-strand Break Signaling Is a Therapeutic Target in Head and Neck Cancer.
Wu J; Galvan KJ; Bogard RD; Peterson CE; Shergill A; Crowe DL
Anticancer Res; 2021 Nov; 41(11):5393-5403. PubMed ID: 34732408
[TBL] [Abstract][Full Text] [Related]
20. The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma.
Shi Q; Shen LY; Dong B; Fu H; Kang XZ; Yang YB; Dai L; Yan WP; Xiong HC; Liang Z; Chen KN
Cancer Lett; 2018 Sep; 432():56-68. PubMed ID: 29890208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
